Mechanism of action and receptor profile
The pharmacodynamics of fluoxetine (Fluoxetinum) is based on its ability to interfere with synaptic transmission processes in the central nervous system structures. The central mechanism of action is a pronounced blockade of neuronal serotonin reuptake. By preventing the return of mediator molecules to the presynaptic terminal, the drug promotes their accumulation, which prolongs and enhances serotonergic transmission.
When studying the pharmacological profile, it is necessary to consider the degree of drug selectivity. The effect of fluoxetine on the reuptake of another crucial neurotransmitter, noradrenaline, is extremely negligible. However, when conducting a comparative analysis within the group, it should be emphasized that the selectivity of fluoxetine regarding serotonin is estimated to be lower than that of paroxetine.
The receptor profile of fluoxetine favorably compares to drugs of previous generations. It is characterized by the complete absence of $\alpha$-adrenoblocking and antihistamine properties. M-anticholinergic activity is present in the drug, but it is extremely negligible (and, importantly for exam tests, less pronounced than in paroxetine).
Features of psychotropic action and onset of effects
Clinical use of antidepressants requires the physician to have a clear understanding of their psychotropic profile. Fluoxetine possesses specific characteristics that sharply distinguish it from classical tricyclic antidepressants. The main difference is the complete absence of a sedative component in its spectrum of action—the drug does not cause lethargy or sluggishness.
On the contrary, the pharmacological profile of this agent includes a moderate psychostimulatory effect. This property determines the clinical appearance of the patient receiving therapy and requires careful attention to dosing.
A crucial aspect of pharmacodynamics is the speed of the therapeutic response onset. The thymoleptic (antidepressant) action of fluoxetine is strictly delayed in time. The development of a full clinical effect occurs not immediately, but exclusively after 1–3 weeks of continuous and regular administration of the drug. Knowledge of this fact is critically important for correctly assessing treatment efficacy and preventing unjustified discontinuation of the drug in the first days of treatment.
Safety and specific adverse reactions
Safety issues play a decisive role in modern psychopharmacology. Due to high selectivity and a favorable receptor profile, fluoxetine demonstrates low toxicity compared to traditional tricyclic antidepressants.
Nevertheless, the enhancement of serotonergic transmission and the psychostimulatory profile cause a number of specific side effects:
- Psychoneurological disorders: nervousness, headaches, and severe insomnia may occur during administration. Particular attention should be paid to the risk of developing akathisia, a distressing syndrome of motor restlessness in which the patient experiences a constant inner urge to move.
- Effect on eating behavior: the drug has a pronounced anorexigenic effect. Clinically, this manifests as an appetite disorder toward its noticeable decrease.
Comparative characteristics with other antidepressants
For a deep understanding of fluoxetine's place among other psychotropic agents, students must be able to conduct a comparative analysis:
- Comparison with tricyclic antidepressants (TCAs): Fluoxetine significantly wins due to its low toxicity. Unlike TCAs, it is completely devoid of a sedative component and also lacks $\alpha$-adrenoblocking and antihistamine properties.
- Comparison with paroxetine: Although both drugs belong to agents affecting serotonin metabolism, fluoxetine is inferior to paroxetine in terms of serotonin selectivity. At the same time, the M-anticholinergic activity of fluoxetine is even more negligible than that of paroxetine.
Briefly: answers to topical questions
To which pharmacological group of antidepressants does fluoxetine belong?
Fluoxetine belongs to the pharmacological group of selective serotonin reuptake inhibitors (SSRIs). The mechanism of action of this antidepressant is that it selectively impairs neuronal serotonin reuptake. This leads to an increase in serotonin concentration in the synaptic cleft. Meanwhile, the drug's effect on noradrenaline reuptake remains negligible.
What psychoneurological side effects does fluoxetine cause?
Psychoneurological side effects of fluoxetine include various motor and psychoemotional disorders.
The main adverse reactions include:
- Akathisia — motor restlessness and inability to sit still.
- Insomnia — sleeplessness.
- Nervousness — increased excitability.
- Headache — pain syndrome.
Additionally, sedation, tremor, and dizziness may occur during treatment.
What are the symptoms of fluoxetine overdose and supportive measures?
SSRIs are considered relatively safe even in high doses. However, with a sharp increase in fluoxetine dose, serotonin syndrome may develop.
Symptoms of the condition:
- Initial manifestations — increased bowel movements, flatulence, anxiety, muscle twitching, profuse sweating, tremor, and coordination impairment.
- Progression — chaotic agitation, altered consciousness, and severe cardiovascular disorders, up to fatal outcome.
Supportive measures:
- Immediate discontinuation of all antidepressants and antipsychotics.
- Use of tranquilizers, for example, diazepam.
- Use of $\beta$-blockers.
- Administration of cyproheptadine as an antiserotonin agent.
- Ice cooling for hyperthermia.
For quick memorization of the pharmacological profile, use the association with the word "FOCUS": F — Fluoxetine. O — Onset delayed (thymoleptic effect develops in 1–3 weeks). C — Kinetics (akathisia — motor restlessness as a frequent side effect). U — Up-regulation / moderate stimulation (psychostimulatory profile, absence of sedation). S — Serotonin (reuptake blockade, selectivity lower than paroxetine).
Class and exam questions
When does the antidepressant effect of fluoxetine develop?
The thymoleptic (antidepressant) action of the drug is delayed. A sustained clinical effect develops only after 1–3 weeks of regular intake.
Does fluoxetine possess a sedative effect?
No, unlike tricyclic antidepressants, fluoxetine is completely devoid of a sedative component. On the contrary, it is characterized by a moderate psychostimulating effect.
How does fluoxetine affect the patient's appetite?
The drug possesses a specific anorexigenic effect. This means that during its intake, patients frequently experience an appetite disorder in the form of its decrease.
What is akathisia occurring during fluoxetine intake?
Akathisia is one of the psychoneurological side effects of the drug, which manifests as pronounced motor restlessness and the patient's inability to remain still.
What else to study on this topic
- Detailed mechanism of neuronal serotonin reuptake in the synapse.
- Comparative pharmacodynamics of fluoxetine and paroxetine.
- Pathogenesis of akathisia and insomnia development during antidepressant therapy.
- Causes of low toxicity compared to tricyclic antidepressants.
- Mechanisms of the anorexigenic effect of psychotropic drugs.
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Fluoxetine" and another 5,304 subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Agents Used in Psychiatry and Neurology"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.